[Current status and future direction of postoperative adjuvant therapy in breast cancer].
The Panel of the St. Gallen 2011 consensus meeting considered the major breast cancer subtypes classified by the expression of hormone receptors and HER2, and the Ki67-labelling index was substituted for microarray-based intrinsic subtypes. When choosing a treatment strategy for breast cancer, the biological property of the tumor itself is given greater importance than the anatomical spreading in the hosts recently. The treatment strategy of adjuvant therapies for breast cancer will be decided according to these simplified intrinsic subtypes: luminal A, luminal B, HER2 positive, and triple negative. The biological markers and targeted therapies will contribute to the advancement of personalized medicine.